A prespecified analysis of the SELECT trial examining whether semaglutide 2.4 mg reduces cardiovascular and heart failure outcomes in patients with obesity and prevalent heart failure. PICO summary and expert commentary.
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
A prespecified SELECT analysis shows semaglutide reduced cardiovascular events in overweight or obese adults without diabetes regardless of baseline HbA1c or HbA1c change. PICO summary and expert commentary.
A prespecified FLOW analysis found once-weekly semaglutide 1 mg lowered the composite of heart failure events or cardiovascular death by 27 percent in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
A secondary analysis of the SELECT trial examined whether weekly semaglutide 2.4 mg lowered all-cause, cardiovascular, non-cardiovascular, and COVID-19-related death in adults with overweight or obesity and cardiovascular disease without diabetes. PICO summary and expert commentary.
A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials showing semaglutide benefits were consistent across baseline inflammation strata. PICO summary and expert commentary.
Prespecified secondary analysis of the STEP-HFpEF Program testing whether semaglutide 2.4 mg benefits in obesity-related HFpEF differ by atrial fibrillation history. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found that once-weekly semaglutide 2.4 mg attenuated left atrial and right ventricular remodelling versus placebo, without changing left ventricular systolic function. PICO summary and expert commentary.
How patient and public involvement shaped the design of ASCEND PLUS, a decentralised RCT of oral semaglutide for cardiovascular prevention in type 2 diabetes. PICO summary and expert commentary.
A 32-week post hoc MRI substudy of 80 patients with type 2 diabetes finds semaglutide and empagliflozin each reduce cortical ADC and total kidney volume, with combination therapy lowering kidney volume most. PICO summary and expert commentary.
A pre-specified secondary analysis of the SELECT trial found that once-weekly semaglutide 2.4 mg modestly reduced a composite kidney endpoint versus placebo in adults with overweight or obesity and established cardiovascular disease, without diabetes. PICO summary and expert commentary.